<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555552</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00089633</org_study_id>
    <nct_id>NCT03555552</nct_id>
  </id_info>
  <brief_title>Point of Care Testing to Improve Monitoring of LVAD Patients</brief_title>
  <official_title>Point of Care Testing to Improve Monitoring of LVAD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and validate the accuracy of a low-cost
      &quot;point-of-care&quot; test (POCT) that allows monitoring of markers for anticoagulation and
      thrombosis (local coagulation or clotting of the blood), to be used by patients with advanced
      heart failure (AHF) on left ventricular assist device (LVAD) support. The investigators
      central hypothesis is that the fully-printed AT-POCT utilizing low-cost (printed) cassettes
      and detector will produce an inexpensive and convenient option for daily self-monitoring of
      PT/INR and LDH over existing methods.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interclass correlation between PT/INR and LDH measurements</measure>
    <time_frame>1 study day</time_frame>
    <description>The primary outcome is acceptable inter-rater agreement between our measure and the clinical gold standards for both PT/INR and LDH. This will be defined as an interclass correlation of &gt; 0.8 with a CI lower bound of 0.1 based on the sample size of this study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anticoagulation and Thrombosis Point of Care Test (AT-POCT)</condition>
  <arm_group>
    <arm_group_label>Anticoagulation and Thrombosis Point of Care Test (AT-POCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Duke Central Automated Laboratory (DCAL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anticoagulation and Thrombosis Point of Care Test(AT-POCT)</intervention_name>
    <description>Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.</description>
    <arm_group_label>Anticoagulation and Thrombosis Point of Care Test (AT-POCT)</arm_group_label>
    <arm_group_label>Duke Central Automated Laboratory (DCAL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Duke Central Automated Laboratory (DCAL)</intervention_name>
    <description>DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.</description>
    <arm_group_label>Anticoagulation and Thrombosis Point of Care Test (AT-POCT)</arm_group_label>
    <arm_group_label>Duke Central Automated Laboratory (DCAL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 80 years of age

          -  Subject has signed Informed Consent Form (ICF)

          -  For LVAD patient cohort, they are on LVAD support from 2 weeks to 10 years.

        Exclusion Criteria:

          -  Patients with dementia, altered mental status, any psychiatric condition or mental
             disability that would prohibit the understanding or rendering of informed consent are
             not eligible

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashutosh Chilkoti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han Billard, MD</last_name>
    <phone>919-385-2306</phone>
    <email>han.billard@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Han Billard, MD</last_name>
      <phone>919-385-2306</phone>
      <email>han.billard@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

